Article

Drug Repurposing for Parkinson’s Disease: A Large-Scale Multi-Cohort Study

2025-05-21

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> Progress in Parkinson’s disease (PD) is hampered by two critical obstacles: the lack of disease-modifying drugs and the difficulty of identify individuals at early, prodromal disease stages for clinical trials. <h4>Methods</h4> We conducted a retrospective, multi-cohort study using data from the Mass General Brigham (MGB) Biobank for discovery and the Accelerating Medicines Par...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 97b9629f-7839-5cfb-9f69-27aba30fe718
DOI: 10.1101/2025.05.20.25327943

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug Repurposing for Parkinson’s Disease: A Large-Scale Multi-Cohort StudyDOI 10.1101/2025.05.20.25327943Read

Retrospective Case-Control Study of Pre-Diagnosis Observational and Prescription Data in Parkinson’s DiseaseSemantic proximity Read

Repurposing the Memory-promoting Meclofenoxate Hydrochloride as a Treatment for Parkinson‘s Disease through Integrative Multi-omics analysisSemantic proximity Read

Parkinson’s Disease: From Gene–Environment Risk to Precision TherapySemantic proximity Read

Finding drug targeting mechanisms with genetic evidence for Parkinson’s diseaseSemantic proximity Read

Disease‑Modifying Therapies for Parkinson’s Disease: Biological Mechanisms, Pharmacological Strategies, and Clinical PipelineSemantic proximity Read

Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.Semantic proximity Read

A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?Semantic proximity Read

Precision medicine for Parkinson’s disease: The subtyping challengeSemantic proximity Read

Identification of Parkinson PACE subtypes and repurposing treatments through integrative analyses of multimodal clinical progression, neuroimaging, genetic, and transcriptomic dataSemantic proximity Read

Constructing Parkinson's disease progression- endotype molecular networks for drug repurposing: multi-omics evidence aggregation and large-scale real-world data validationSemantic proximity Read

Integration of National Health Insurance Claim Data and Animal Models Reveals Fexofenadine as a Promising Repurposed Drug for Parkinson’s DiseaseSemantic proximity Read

Health phenome of Parkinson’s patients reveals prominent mood-sleep clusterSemantic proximity Read